Table 1.

Relative risks of SPCs among all multiple myeloma patients stratified over family

Cancer	At least 1 FDR with cancer			No FDR with cancer			Total			Trend test P value
	N	RR	95% CI	N	RR	95% CI	N	RR	95% CI
Colorectum	7	2.10	1.00–4.41	27	1.01	0.69–1.47	34	1.13	0.81–1.58	0.033
Lung	3	5.40	1.74–16.75	10	1.13	0.61–2.10	13	1.38	0.80–2.38	0.061
Breast	4	1.13	0.42–3.01	24	0.93	0.62–1.39	28	0.95	0.66–1.38	0.176
Prostate	20	1.60	1.03–2.48	38	0.56	0.41–0.77	58	0.72	0.56–0.93	0.006
Melanoma	2	5.04	1.26–20.14	18	1.46	0.92–2.32	20	1.57	1.01–2.44	0.087
Skin (SCC)	4	8.82	3.31–23.52	31	2.58	1.81–3.67	35	2.81	2.01–3.91	0.029
Leukemia	2	9.14	2.29–36.55	32	4.41	3.11–6.24	34	4.55	3.25–6.37	0.093
All	246	1.38	1.22–1.57	114	1.13	0.94–1.36	360	1.29	1.17–1.43	<0.001

Bold, italics and underline indicate 5%, 1% and 0.1% level of significance

FDR first degree relative, N frequency, RR relative risk, CI confidence interval, SCC squamous cell carcinoma